Lytix Biopharma AS (6BG) Stock Statistics & Valuation Metrics

Lytix Biopharma AS has a market cap or net worth of €67.96M. The enterprise value is ―.

Lytix Biopharma AS has 76,900,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lytix Biopharma AS’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -100.12%.

The current PE Ratio of Lytix Biopharma AS is ―. Lytix Biopharma AS’s PEG ratio is ―.

In the last 12 months, Lytix Biopharma AS had revenue of 0.00 and earned -59.98M in profits. Earnings per share was -0.88.

In the last 12 months, operating cash flow was -75.74M and capital expenditures 0.00, giving a free cash flow of -75.74M billion.

Lytix Biopharma AS pays an annual dividend of ―, resulting in a dividend yield of ―

Lytix Biopharma AS upcoming earnings date is Aug 27, 2026, Before Open (Confirmed).

Lytix Biopharma AS as a current ratio of 4.28, with Debt / Equity ratio of 1.76%

In the past 12 months, Lytix Biopharma AS has paid 0.00 in taxes.

Lytix Biopharma AS EV to EBITDA ratio is -10.63, with an EV/FCF ratio of 0.00.

Lytix Biopharma AS has €120.17M in cash and marketable securities with €2.88M in debt, giving a net cash position of €118.16M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Lytix Biopharma AS is ―, which is 11.43% higher than the current price. The consensus rating is ―